Biopsy Devices Market - By Product [Robotic systems, Biopsy Needle (Disposable, Reusable), Biopsy Forceps, Fine Needle Aspiration, Punches], By End User [Hospitals, Clinics], By Region - Global Forecast to 2032

Biopsy Devices Market Size

Biopsy Devices Market size exceeded USD 2 billion in 2022 and is anticipated to depict over 6% CAGR through 2023-2032. Increasing prevalence of breast cancer along with strong awareness about innovative diagnostic equipment availability will boost the global industry growth.

The introduction of multiple educational campaigns has increased awareness about cancer and its diagnosis, while the risk of breast cancer has also risen over the years. According to the American Cancer Society's report, women in the United States have a 12% lifetime risk of developing breast cancer. These factors are expected to drive the demand for biopsy equipment and supplies, which are used to remove small pieces of breast tissue to detect cancer cells. The general population is also becoming more aware of the availability of innovative diagnostic equipment, which is likely to further boost the development of breast biopsy devices.
 

Despite the benefits of using biopsy devices, randomized trials have shown that there are potential complications associated with their use. For example, a trial conducted in Europe identified major issues related to prostate needle biopsy, including fever episodes, urinary tract infection, transitory bacteremia, urinary retention, and sepsis. In addition, excessive bleeding, drainage from biopsy sites, and swelling due to infections or sepsis have also been reported among users, which may limit the use of needle biopsy devices to some extent.
 

Biopsy Devices Market Analysis

Biopsy devices market value from the biopsy forceps is set to surpass USD 170 million by 2032, on account of the surge in cases of skin disorders including eczema. Furthermore, there has been an increase in the number of biopsy procedures among patients with skin disorders. These factors, alongside the introduction of superior products for convenient and rapid sample collection, will stimulate the use of equipment such as biopsy forceps.
 

Biopsy devices market from ambulatory surgery center is expected to exhibit a CAGR of over 7.5% between 2023 and 2032 due to the affordability and range of healthcare services provided through ASCs. According to data from the Centers for Medicare & Medicaid Services, the number of these surgical centers is increasing by an average of 1.7% annually, while procedures and services have grown at a rate of 2.7% in recent years. As a result, more patients are likely to choose biopsy procedures in ambulatory surgical centers, which will increase the demand for biopsy devices.
 

North America region accounted for more than 52% of the global biopsy devices market in 2022, primarily due to its well-established healthcare infrastructure. Additionally, the increasing prevalence of infectious diseases has resulted in the widespread acceptance of point-of-care diagnostic devices for early and safe disease detection. The region's advanced insurance and co-payment systems have also contributed to its dominance in the market. Furthermore, the presence of major industry players in the region is expected to drive the development and proliferation of biopsy equipment in North America.
 

Middle East and Africa biopsy devices market value is projected to surpass USD 110 million by 2032, driven by the introduction of government initiatives to support cancer patients. Additionally, several manufacturers and non-government organizations have adopted advanced technology to support healthcare service providers, thereby boosting the development of biopsy devices in the region.
 

Biopsy Devices Market Share

• Medtronic plc
• Olympus Corporation
• Boston Scientific Corporation
• Becton
• Dickinson and Company (BD)
• FUJIFILM Holdings Corporation
• Argon Medical Devices
• Cardinal Health
• Hologic Inc., Inc
• B. Braun Melsungen AG
• Cook Group Incorporated
• Devicor Medical Products, Inc. (Danaher Corporation)
• INRAD Inc
• Stryker Corporation

are some of the key players operating in the global biopsy devices industry. These companies are focusing on mergers and acquisitions and other strategies to strengthen their presence in the industry.
 

Impact of COVID-19 Pandemic

The COVID-19 pandemic and the subsequent lockdowns and stringent regulations had a significant impact on the global economy and various industry verticals, including healthcare. In April 2020, the healthcare sector, as well as radiology practices and academic radiology departments, experienced financial consequences. Additionally, breast screening programs were halted in countries such as England during the initial months of the pandemic. These factors may have reduced the acceptance of biopsy diagnostic procedures among cancer patients and hindered the expansion of the industry to some extent.
 

The biopsy devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product

• Biopsy guidance systems
  • Manual
  • Robotic
• Needle based biopsy guns
  • Vacuum-assisted biopsy (VAB) devices
  • Fine needle aspiration biopsy (FNAB) devices
  • Core needle biopsy (CNB) devices
• Biopsy needles
  • Disposable
  • Reusable
• Biopsy forceps
  • General biopsy forceps
  • Hot biopsy forceps
• Others
  • Brushes
  • Curettes
  • Punches

By End-use

• Hospitals
• Ambulatory surgical center
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Others
• Asia Pacific
  • Japan
  • China
  • India
  • Others
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Others
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Others